Loading…
Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis
Objective To assess the clinical relevance of increased circulating cytokines in patients with giant cell arteritis (GCA) after long‐term followup. Methods We performed a cross‐sectional evaluation of 54 patients with biopsy‐proven GCA prospectively followed for a median of 5.4 years (range 4–10.5 y...
Saved in:
| Published in: | Arthritis care & research (2010) 2010-06, Vol.62 (6), p.835-841 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613 |
| container_end_page | 841 |
| container_issue | 6 |
| container_start_page | 835 |
| container_title | Arthritis care & research (2010) |
| container_volume | 62 |
| creator | García‐Martínez, Ana Hernández‐Rodríguez, José Espígol‐Frigolé, Georgina Prieto‐González, Sergio Butjosa, Montserrat Segarra, Marta Lozano, Ester Cid, Maria C. |
| description | Objective
To assess the clinical relevance of increased circulating cytokines in patients with giant cell arteritis (GCA) after long‐term followup.
Methods
We performed a cross‐sectional evaluation of 54 patients with biopsy‐proven GCA prospectively followed for a median of 5.4 years (range 4–10.5 years). GCA‐related complications, vascular events, relapses, current prednisone dose, time required to achieve a maintenance prednisone dosage |
| doi_str_mv | 10.1002/acr.20043 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733263598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733263598</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613</originalsourceid><addsrcrecordid>eNp1kU1OHDEQha0IFBBhkQtEtQssBuy2-2-JRkCQkCJFRMqu5XaXBydue2K7Gc2OI3CV5CA5BCeJZ4awize2q756z_Ij5D2jZ4zS4lyqcFZQKvgbcliwks1EVTZ7r2fx7YAcx_id5sWLpuHtW3JQ0JKXdSsOye-5Nc4oaSGgxQfpFILXsMQQTUzokl3DtpFwAGWCmqxMxi1ArZP_YRxGOEnT6AM4VMHnIdBSpXz_8wukG8C4hMHilNnnx6fqNBcg3SNY7xa5kJsjaG-tX03LrXOWz7YRVibdw8JIl0ChtSBDZk0y8R3Z19JGPH7Zj8jXq8u7-afZ7efrm_nF7UzxsuWzSjaV7FvFGsVKTnvBetZi0fO65Y1QSijOBR1qKRht9FBq2vZcy7pSVNe0YvyIfNzpLoP_OWFM3Wji5inSoZ9iV3NeVNmqyeTpjtz8QAyou2UwowzrjtFuE1KXQ-q2IWX2w4vq1I84vJL_IsnA-Q5YGYvr_yt1F_MvO8m_UbSh1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733263598</pqid></control><display><type>article</type><title>Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis</title><source>Wiley</source><creator>García‐Martínez, Ana ; Hernández‐Rodríguez, José ; Espígol‐Frigolé, Georgina ; Prieto‐González, Sergio ; Butjosa, Montserrat ; Segarra, Marta ; Lozano, Ester ; Cid, Maria C.</creator><creatorcontrib>García‐Martínez, Ana ; Hernández‐Rodríguez, José ; Espígol‐Frigolé, Georgina ; Prieto‐González, Sergio ; Butjosa, Montserrat ; Segarra, Marta ; Lozano, Ester ; Cid, Maria C.</creatorcontrib><description>Objective
To assess the clinical relevance of increased circulating cytokines in patients with giant cell arteritis (GCA) after long‐term followup.
Methods
We performed a cross‐sectional evaluation of 54 patients with biopsy‐proven GCA prospectively followed for a median of 5.4 years (range 4–10.5 years). GCA‐related complications, vascular events, relapses, current prednisone dose, time required to achieve a maintenance prednisone dosage <10 mg/day, cumulated prednisone at that point, and adverse effects during followup were recorded. Serum interleukin‐6 (IL‐6) and tumor necrosis factor α (TNFα) were determined by immunoassay.
Results
All patients were in clinical remission. Both cytokines were significantly higher in patients than in controls (mean ± SD 21 ± 35 versus 5 ± 11 pg/ml; P < 0.001 for IL‐6 and mean ± SD 32 ± 14 versus 16 ± 9 pg/ml; P < 0.001 for TNFα). No differences were found in patients with or without GCA‐related complications or vascular events during followup. Circulating cytokines were significantly higher in patients who had experienced relapses (mean ± SD 25 ± 39 versus 10 ± 11 pg/ml; P = 0.04 for IL‐6 and mean ± SD 34 ± 15 versus 25 ± 11 pg/ml; P = 0.042 for TNFα). IL‐6 was significantly higher in patients still requiring prednisone (mean ± SD 29 ± 45 versus 13 ± 17 pg/ml; P = 0.008), and TNFα correlated with cumulated prednisone dose (r = 0.292, P = 0.04). No significant relationship was found between elevated cytokines and prednisone adverse effects or patients' quality of life.
Conclusion
Circulating TNFα and IL‐6 may persist elevated in GCA patients after long‐term followup and remain higher in patients who have experienced more relapsing disease. However, in this patient cohort, elevated circulating cytokines were not associated with increased frequency of GCA complications, vascular events, or treatment‐related side effects.</description><identifier>ISSN: 2151-464X</identifier><identifier>EISSN: 2151-4658</identifier><identifier>DOI: 10.1002/acr.20043</identifier><identifier>PMID: 20535794</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; Aged, 80 and over ; Biomarkers - blood ; Cohort Studies ; Cross-Sectional Studies ; Female ; Follow-Up Studies ; Giant Cell Arteritis - blood ; Giant Cell Arteritis - diagnosis ; Humans ; Interleukin-6 - blood ; Male ; Middle Aged ; Prospective Studies ; Recurrence ; Time Factors ; Tumor Necrosis Factor-alpha - blood</subject><ispartof>Arthritis care & research (2010), 2010-06, Vol.62 (6), p.835-841</ispartof><rights>Copyright © 2010 by the American College of Rheumatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613</citedby><cites>FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Facr.20043$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Facr.20043$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20535794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García‐Martínez, Ana</creatorcontrib><creatorcontrib>Hernández‐Rodríguez, José</creatorcontrib><creatorcontrib>Espígol‐Frigolé, Georgina</creatorcontrib><creatorcontrib>Prieto‐González, Sergio</creatorcontrib><creatorcontrib>Butjosa, Montserrat</creatorcontrib><creatorcontrib>Segarra, Marta</creatorcontrib><creatorcontrib>Lozano, Ester</creatorcontrib><creatorcontrib>Cid, Maria C.</creatorcontrib><title>Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis</title><title>Arthritis care & research (2010)</title><addtitle>Arthritis Care Res (Hoboken)</addtitle><description>Objective
To assess the clinical relevance of increased circulating cytokines in patients with giant cell arteritis (GCA) after long‐term followup.
Methods
We performed a cross‐sectional evaluation of 54 patients with biopsy‐proven GCA prospectively followed for a median of 5.4 years (range 4–10.5 years). GCA‐related complications, vascular events, relapses, current prednisone dose, time required to achieve a maintenance prednisone dosage <10 mg/day, cumulated prednisone at that point, and adverse effects during followup were recorded. Serum interleukin‐6 (IL‐6) and tumor necrosis factor α (TNFα) were determined by immunoassay.
Results
All patients were in clinical remission. Both cytokines were significantly higher in patients than in controls (mean ± SD 21 ± 35 versus 5 ± 11 pg/ml; P < 0.001 for IL‐6 and mean ± SD 32 ± 14 versus 16 ± 9 pg/ml; P < 0.001 for TNFα). No differences were found in patients with or without GCA‐related complications or vascular events during followup. Circulating cytokines were significantly higher in patients who had experienced relapses (mean ± SD 25 ± 39 versus 10 ± 11 pg/ml; P = 0.04 for IL‐6 and mean ± SD 34 ± 15 versus 25 ± 11 pg/ml; P = 0.042 for TNFα). IL‐6 was significantly higher in patients still requiring prednisone (mean ± SD 29 ± 45 versus 13 ± 17 pg/ml; P = 0.008), and TNFα correlated with cumulated prednisone dose (r = 0.292, P = 0.04). No significant relationship was found between elevated cytokines and prednisone adverse effects or patients' quality of life.
Conclusion
Circulating TNFα and IL‐6 may persist elevated in GCA patients after long‐term followup and remain higher in patients who have experienced more relapsing disease. However, in this patient cohort, elevated circulating cytokines were not associated with increased frequency of GCA complications, vascular events, or treatment‐related side effects.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers - blood</subject><subject>Cohort Studies</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Giant Cell Arteritis - blood</subject><subject>Giant Cell Arteritis - diagnosis</subject><subject>Humans</subject><subject>Interleukin-6 - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Time Factors</subject><subject>Tumor Necrosis Factor-alpha - blood</subject><issn>2151-464X</issn><issn>2151-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp1kU1OHDEQha0IFBBhkQtEtQssBuy2-2-JRkCQkCJFRMqu5XaXBydue2K7Gc2OI3CV5CA5BCeJZ4awize2q756z_Ij5D2jZ4zS4lyqcFZQKvgbcliwks1EVTZ7r2fx7YAcx_id5sWLpuHtW3JQ0JKXdSsOye-5Nc4oaSGgxQfpFILXsMQQTUzokl3DtpFwAGWCmqxMxi1ArZP_YRxGOEnT6AM4VMHnIdBSpXz_8wukG8C4hMHilNnnx6fqNBcg3SNY7xa5kJsjaG-tX03LrXOWz7YRVibdw8JIl0ChtSBDZk0y8R3Z19JGPH7Zj8jXq8u7-afZ7efrm_nF7UzxsuWzSjaV7FvFGsVKTnvBetZi0fO65Y1QSijOBR1qKRht9FBq2vZcy7pSVNe0YvyIfNzpLoP_OWFM3Wji5inSoZ9iV3NeVNmqyeTpjtz8QAyou2UwowzrjtFuE1KXQ-q2IWX2w4vq1I84vJL_IsnA-Q5YGYvr_yt1F_MvO8m_UbSh1g</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>García‐Martínez, Ana</creator><creator>Hernández‐Rodríguez, José</creator><creator>Espígol‐Frigolé, Georgina</creator><creator>Prieto‐González, Sergio</creator><creator>Butjosa, Montserrat</creator><creator>Segarra, Marta</creator><creator>Lozano, Ester</creator><creator>Cid, Maria C.</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201006</creationdate><title>Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis</title><author>García‐Martínez, Ana ; Hernández‐Rodríguez, José ; Espígol‐Frigolé, Georgina ; Prieto‐González, Sergio ; Butjosa, Montserrat ; Segarra, Marta ; Lozano, Ester ; Cid, Maria C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers - blood</topic><topic>Cohort Studies</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Giant Cell Arteritis - blood</topic><topic>Giant Cell Arteritis - diagnosis</topic><topic>Humans</topic><topic>Interleukin-6 - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Time Factors</topic><topic>Tumor Necrosis Factor-alpha - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García‐Martínez, Ana</creatorcontrib><creatorcontrib>Hernández‐Rodríguez, José</creatorcontrib><creatorcontrib>Espígol‐Frigolé, Georgina</creatorcontrib><creatorcontrib>Prieto‐González, Sergio</creatorcontrib><creatorcontrib>Butjosa, Montserrat</creatorcontrib><creatorcontrib>Segarra, Marta</creatorcontrib><creatorcontrib>Lozano, Ester</creatorcontrib><creatorcontrib>Cid, Maria C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis care & research (2010)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García‐Martínez, Ana</au><au>Hernández‐Rodríguez, José</au><au>Espígol‐Frigolé, Georgina</au><au>Prieto‐González, Sergio</au><au>Butjosa, Montserrat</au><au>Segarra, Marta</au><au>Lozano, Ester</au><au>Cid, Maria C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis</atitle><jtitle>Arthritis care & research (2010)</jtitle><addtitle>Arthritis Care Res (Hoboken)</addtitle><date>2010-06</date><risdate>2010</risdate><volume>62</volume><issue>6</issue><spage>835</spage><epage>841</epage><pages>835-841</pages><issn>2151-464X</issn><eissn>2151-4658</eissn><notes>Presented in part at the 70th Annual Scientific Meeting of the American College of Rheumatology, Washington, DC, November 2006, and at the 13th International Vasculitis Meeting and ANCA Workshop, Cancun, Mexico, April 2007.</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Objective
To assess the clinical relevance of increased circulating cytokines in patients with giant cell arteritis (GCA) after long‐term followup.
Methods
We performed a cross‐sectional evaluation of 54 patients with biopsy‐proven GCA prospectively followed for a median of 5.4 years (range 4–10.5 years). GCA‐related complications, vascular events, relapses, current prednisone dose, time required to achieve a maintenance prednisone dosage <10 mg/day, cumulated prednisone at that point, and adverse effects during followup were recorded. Serum interleukin‐6 (IL‐6) and tumor necrosis factor α (TNFα) were determined by immunoassay.
Results
All patients were in clinical remission. Both cytokines were significantly higher in patients than in controls (mean ± SD 21 ± 35 versus 5 ± 11 pg/ml; P < 0.001 for IL‐6 and mean ± SD 32 ± 14 versus 16 ± 9 pg/ml; P < 0.001 for TNFα). No differences were found in patients with or without GCA‐related complications or vascular events during followup. Circulating cytokines were significantly higher in patients who had experienced relapses (mean ± SD 25 ± 39 versus 10 ± 11 pg/ml; P = 0.04 for IL‐6 and mean ± SD 34 ± 15 versus 25 ± 11 pg/ml; P = 0.042 for TNFα). IL‐6 was significantly higher in patients still requiring prednisone (mean ± SD 29 ± 45 versus 13 ± 17 pg/ml; P = 0.008), and TNFα correlated with cumulated prednisone dose (r = 0.292, P = 0.04). No significant relationship was found between elevated cytokines and prednisone adverse effects or patients' quality of life.
Conclusion
Circulating TNFα and IL‐6 may persist elevated in GCA patients after long‐term followup and remain higher in patients who have experienced more relapsing disease. However, in this patient cohort, elevated circulating cytokines were not associated with increased frequency of GCA complications, vascular events, or treatment‐related side effects.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>20535794</pmid><doi>10.1002/acr.20043</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2151-464X |
| ispartof | Arthritis care & research (2010), 2010-06, Vol.62 (6), p.835-841 |
| issn | 2151-464X 2151-4658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733263598 |
| source | Wiley |
| subjects | Aged Aged, 80 and over Biomarkers - blood Cohort Studies Cross-Sectional Studies Female Follow-Up Studies Giant Cell Arteritis - blood Giant Cell Arteritis - diagnosis Humans Interleukin-6 - blood Male Middle Aged Prospective Studies Recurrence Time Factors Tumor Necrosis Factor-alpha - blood |
| title | Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T08%3A34%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20relevance%20of%20persistently%20elevated%20circulating%20cytokines%20(tumor%20necrosis%20factor%20%CE%B1%20and%20interleukin%E2%80%906)%20in%20the%20long%E2%80%90term%20followup%20of%20patients%20with%20giant%20cell%20arteritis&rft.jtitle=Arthritis%20care%20&%20research%20(2010)&rft.au=Garc%C3%ADa%E2%80%90Mart%C3%ADnez,%20Ana&rft.date=2010-06&rft.volume=62&rft.issue=6&rft.spage=835&rft.epage=841&rft.pages=835-841&rft.issn=2151-464X&rft.eissn=2151-4658&rft_id=info:doi/10.1002/acr.20043&rft_dat=%3Cproquest_cross%3E733263598%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3593-6a86ab9c18c1530b41b19e2b379384cc4c3340d7a4108fd5f09b3fa76c0f70613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733263598&rft_id=info:pmid/20535794&rfr_iscdi=true |